Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques

Journal of Virology

Volumn 73, Issue 4, 1999, Pages 2947-2955

  Van Rompay, Koen K A ^a   Dailey, Peter J ^c   Tarara, Ross P ^a   Canfield, Don R ^a   Aguirre, Nancy L ^a   Cherrington, Julie M ^d   Lamy, Patrick D ^c   Bischofberger, Norbert ^c   Pedersen, Niels C ^b   Marthas, Marta L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; STAVUDINE; TENOFOVIR;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; HELPER CELL; IMMUNOREGULATION; INOCULATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; TREATMENT OUTCOME; VIREMIA; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

EID: 0032974787     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.4.2947-2955.1999     Document Type: Article

References (57)

1. Ammann, A. J. 1994. Human immunodeficiency virus infection/AIDS in children: the next decade. Pediatrics 93:930-935.
2. Blanche, S., C. Rouzioux, M.-L. Guihard Moscato, F. Veber, M.-J. Mayaux, C. Jacomet, J. Tricoire, A. Deville, M. Vial, G. Firtion, A. de Crepy, D. Douard, M. Robin, C. Courpotin, N. Ciraru-Vigneron, F. le Deist, C. Griscelli, and the HIV Infection in Newborns French Collaborative Study Group. 1989. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. N. Engl. J. Med. 320:1643-1648.
3. Borkowsky, W., K. Krasinki, D. Paul, R. Holzman, T. Moore, D. Bebenroth, R. Lawrence, and S. Chandwani. 1989. Human immunodeficiency virus type 1 antigenemia in children. J. Pediatr. 114:940-945.
4. Centers for Disease Control and Prevention. 1997. Update: perinatally acquired HIV/AIDS - United States, 1997. Morbid. Mortal. Weekly Rep. 46: 1086-1092.
5. Centers for Disease Control and Prevention. 1997. Update: trends in AIDS incidence - United States. 1996. Morbid. Mortal. Weekly Rep. 46:862-867.
6. Centers for Disease Control and Prevention. 1998. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Morbid. Mortal. Weekly Rep. 47(RR-4):1-43.
7. Centers for Disease Control and Prevention. 1998. Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV. including considerations related to antiretroviral therapy. Public Health Service statement. Morbid. Mortal. Weekly Rep. 47(RR-17):1-14.
8. Centers for Disease Control and Prevention. 1998. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Morbid. Mortal. Weekly Rep. 47(RR-7):1-34.
9. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
10. Connor, E. M., R. S. Sperling, R. Gelber, P. Kiselev, G. Scott, M. J. O'Sullivan, R. VanDyke, M. Bey, W. Shearer, R. L. Jacobson, E. Jiminez, E. O'Neill, B. Bazin, J.-F. Delfraissy, M. Culnane, R. Coombs, M. Elkins, J. Moye, P. Stratton and J. Balsley, for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331:1173-1180.
11. Dailey, P. J., M. Zamroud, R. Kelso, J. Kolberg, and M. Urdea. 1995. Quantitation of simian immunodeficiency virus (SIV) RNA in plasma of acute and chronically infected rhesus macaques using a branched DNA (bDNA) signal amplification assay, abstr. 99. In Proceedings of the 13th Annual Symposium on Nonhuman Primate Models of AIDS. Monterey, Calif., 5 to 8 November 1995.
12. Dawson-Saunders, B., and R. G. Trapp. 1990. Basic and clinical biostatistics. Appleton & Lange, Norwalk, Conn.
13. Deeks, S. G., P. Barditch-Crovo, P. S. Lietman, A. Collier, S. Safrin, R. Coleman, K. C. Cundy, and J. O. Kahn. 1998. The safety and efficacy of PMPA prodrug monotherapy: preliminary results of a phase I/II dose-escalation study, abstr. 772. In Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., 1 to 5 February 1998.
14. Deeks, S. G., P. Barditch-Crovo, P. S. Lietman, F. Hwang, K. C. Cundy, J. F. Rooney, N. S. Hellmann, S. Safrin, and J. O. Kahn. 1998. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42:2380-2384.
15. Epstein, L. G., C. A. Boucher, S. H. Morrison, E. M. Connor, J. M. Oleske, J. M. A. Lange, J. van der Noordaa, M. Bakker, J. Dekker, H. Scherpbier, H. van den Berg, K. Boer, and J. Goudsmit. 1988. Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression. Pediatrics 82:919-924.
16. European Collaborative Study. 1991. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 337:253-260.
17. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. J. Piatak, W. R. Elkins, W. G. Alvord, D. C. Montefiori, B. Moss, and J. D. Lifson. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741-3752.
18. Joag, S. V., Z. Li, L. Foresman, D. M. Pinson, E. B. Stephens, R. Raghavan, J.-F. Navé, P. Casara, and O. Narayan. 1997 Early treatment with 9-(2-phosphonylmethoxyethyl)adenine reduces virus burdens for a prolonged period in SIV-infected rhesus macaques. AIDS Res. Hum. Retroviruses 13: 241-246.
19. Kinloch-de Loës, S., B. J. Hirschel, B. Hoen, D. A. Cooper, B. Tindall, A. Carr, J.-H. Saurat, N. Clumeck, A. Lazzarin, L. Mathiesen, F. Raffi, F. Antunes, J. Von Overbeck, R. Lüthy, M. Glauser, D. Hawkins, C. Baumberger, S. Yerly, T. V. Perneger, and L. Perrin. 1995. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N. Engl. J. Med. 333:408-413.
20. Lafeuillade, A., C. Poggi, C. Tamalet, N. Profizi, C. Tourres, and O. Costes, 1997. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J. Infect. Dis. 175: 1051-1055.
21. Lifson, J. D., M. A. Nowak, S. Goldstein, J. L. Rossio, A. Kinter, C. Vasquez, T. Wiltrout, C. Brown, D. Schneider, L. Wahl, A. L. Lloyd, J. Williams, W. R. Elkins, A. S. Fauci, and V. M. Hirsch. 1997. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J. Virol. 71:9508-9514.
22. Lohman, B. L., J. Higgins, M. L. Marthas, P. A. Marx, and N. C. Pedersen. 1991. Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J. Clin. Microbiol. 29:2187-2192.
23. Lü, X., H. Kiyono, D. Lu, S. Kawabata, J. Torten, S. Srinivasan, P. J. Dailey, J. R. McGhee, T. Lehner, and C. J. Miller. 1998. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251. AIDS 12:1-10.
24. Luzuriaga, K., V. Bryson, P. Krogstad, J. Robinson, B. Stechenberg, M. Lamson, S. Cort, and J. Sullivan. 1997. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N. Engl. J. Med. 336:1343-1349.
25. Marthas, M. L., K. K. A. Van Rompay, M. Otsyula, C. J. Miller, D. Canfield, N. C. Pedersen, and M. B. McChesney. 1995. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 69:4198-4205.
26. Miller, M., J. M. Cherrington, P. D. Lamy, A. S. Mulato, and K. E. Anton. 1998. Genotypic changes in HIV RT which develop during Preveon (adefovir dipivoxil) therapy do not decrease susceptibility to PMPA, abstr. 41218. In Proceedings of the 12th World AIDS Conference, Geneva, Switzerland, 28 June to 3 July 1998.
27. Mulato, A. S., P. D. Lamy, M. D. Miller, W.-X. Li, K. E. Anton, N. S. Hellmann, and J. M. Cherrington. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob. Agents Chemother 42:1620-1628.
28. Nahmias, A. J., W. S. Clark, A. P. Kourtis, F. K. Lee, G. Cotsonis, C. Ibegbu, D. Thea, P. Palumbo, P. Vink, K. J. Simonds, and S. R. Nesheim. 1998. Thymic dysfunction and time of infection predict mortality in human immunodeficiency virus-infected infants. J. Infect. Dis. 178:680-685.
29. 28a. National Research Council Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
30. Nowak, M. A., A. L. Lloyd, G. M. Vasquez, T. A. Wiltrout, L. M. Wahl, N. Bischofberger, J. Williams, A. Kinter, A. S. Fauci, V. M. Hirsch, and J. D. Lifson. 1997. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J. Virol. 71:7518-7525.
31. Otsyula, M. G., C. J. Miller, M. L. Marthas, K. K. A. Van Rompay, J. R. Collins, N. C. Pedersen, and M. B. McChesney. 1996. Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus. Pediatr. Res. 39:630-635.
32. Pachl, C., J. A. Todd, D. G. Kern, P. J. Sheridan, S.-J. Fong, M. Stempein, B. Hoo, D. Besemer, T. Yeghiazarian, B. Irvine, J. Kolberg, R. Kokka, P. Neuwald, and M. S. Urdea. 1995. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 8:446-454.
33. Palumbo, P. E., S. Kwok, S. Waters, Y. Wesley, D. Lewis, N. McKinney, A. Bardeguez, E. Connor, and J. M. Oleske. 1995. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J. Pediatr. 126:592-595.
34. Palumbo, P. E., C. Raskino, S. Fiscus, S. Pahwa, M. G. Fowler, S. A. Spector, J. A. Englund, and C. J. Baker. 1998. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 279:756-761.
35. Perrin, L., A. Rakik, S. Yerly, C. Baumberger, S. Kinloch-de Loes, M. Pechere, and B. Hirschel. 1996. Combined therapy with zidovudine and L-697, 661 in primary HIV infection. AIDS 10:1233-1237.
36. Pollack, H., M. X. Zhan, T. Ilmet-Moore, K. Ajuang-Simbiri, K. Krasinski, and W. Borkowsky. 1993. Ontogeny of anti-human immunodeficiency virus (HIV) antibody production in HIV-1-infected infants. Proc. Natl. Acad. Sci. USA 90:2340-2344.
37. Rosenberg, E. S., J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-1450.
38. Saag, M. S., M. J. Crain, W. D. Decker, S. Campbell-Hill, S. Robinson, W. E. Brown, M. Leuther, R. J. Whitley, B. H. Hahn, and G. M. Shaw. 1991. High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels. J. Infect. Dis. 164:72-80.
39. Schacker, T. W., J. P. Hughes, T. Shea, R. W. Coombs, and L. Corey. 1998. Biological and virologic characteristics of primary HIV infection. Ann. Intern. Med. 128:613-620.
40. Scott, G. B., C. Hutto, R. W. Makuch, M. T. Mastrucci, T. O'Connor, C. D. Mitchell, E. J. Trapido, and W. P. Parks. 1989. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N. Engl. J. Med. 321:1791-1796.
41. Tindall, B., A. Carr, D. Goldstein, R. Penny, and D. A. Cooper. 1993. Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response. AIDS 7:127-128
42. mne infection depends critically on timing of initiation and duration of treatment. J. Virol. 72:4265-4273.
43. Tsai, C.-C., K. E. Follis, T. W. Beck, A. Sabo, R. F. Grant, N. Bischofberger, and R. E. Benveniste. 1995. Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl)adenine (PMPA). Science 270:1197-1199.
44. UNAIDS/WHO, 1997. Report on the global HIV/AIDS epidemic. UNAIDS. Geneva, Switzerland. December.
45. Vanhems, P., J. Lambert, D. A. Cooper, L. Perrin, A. Carr, B. Hirschel, J. Vizzard, S. Kinloch-de Loës, and R. Allard. 1998. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin. Infect. Dis. 26:323-329.
46. Van Rompay, K. K. A., C. J. Berardi, N. L. Aguirre, N. Bischofberger, P. S. Lietman, N. C. Pedersen, and M. L. Marthas. 1998. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 12:F79-F83.
47. Van Rompay, K. K. A., C. J. Berardi, S. Dillard-Telm, R. P. Tarara, D. R. Canfield, C. R. Valverde, D. C. Montefiori, K. Stefano Cole, R. C. Montelaro, C. J. Miller, and M. L. Marthas. 1998. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis. 177:1247-1259.
48. Van Rompa, K. K. A., J. M. Cherrington, M. L. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, and N. C. Pedersen. 1996. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.
49. Van Rompay, K. K. A., J. M. Cherrington, M. E. Marthas, P. D. Lamy, P. J. Dailey, D. R. Canfield, R. P. Tarara, N. Bischofberger, and N. C. Pedersen. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob. Agents Chemother., in press.
50. Van Rompay, K. K. A., and M. L. Marthas. Unpublished data.
51. Van Rompay, K. K. A., M. E. Marthas, J. D. Lifson, C. J. Berardi, G. M. Vasquez, E. Agatep, Z. A. Dehqanzada, K. C. Cundy, N. Bischofberger, and N. C. Pedersen. 1998. Administration of 4-[2-(phosphonomethoxy)propyl]-adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res. Hum. Retroviruses 14:761-773.
52. Van Rompay, K. K. A., M. L. Marthas, R. A. Ramos, C. P. Mandell, E. K. McGowan, S. M. Joye, and N. C. Pedersen. 1992. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob. Agents Chemother. 36:2381-2386.
53. Van Rompay, K. K. A., M. G. Otsyula, M. L. Marthas, C. J. Miller, M. B. McChesney, and N. C. Pedersen. 1995. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob. Agents Chemother. 39:125-131.
54. Van Rompay, K. K. A., M. G. Otsyula, R. P. Tarara, D. R. Canfield, C. J. Berardi, M. B. McChesney, and M. L. Marthas. 1996. Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J. Infect. Dis. 173:1327-1335.
55. Vella, P. P., and R. W. Ellis. 1991. Immunogenicity of Haemophilus influenzae type b conjugate vaccines in infant rhesus monkeys. Pediatr. Res. 29:10-13.
56. Watson, A., J. McClure, J. Ranchalis, M. Scheibel, A. Schmidt, B. Kennedy, W. R. Morton, N. L. Haigwood, and S.-L. Hu. 1947. Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques. AIDS Res. Hum. Retroviruses 13:1375-1381.
57. Withers-Ward, E., R. F. Amado, P. S. Koka, B. D. Jamieson, A. H. Kaplan. I. S. Y. Chen, and J. A. Zack. 1997. Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nat. Med. 3:1102-1109.